2013 annual shareholder meeting dwight babcock, ceo
DESCRIPTION
2013 Annual Shareholder Meeting Dwight Babcock, CEO. Innovative Solutions Begins With A Great Team. Fred Swindler Bill Cavanagh Brien Ragle Krista Cline Dale Boyce Clay O’Laughlin. State of Prostate Cancer Treatments. Brachytherapy External Beam Robotic Surgery - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/1.jpg)
2013 Annual Shareholder Meeting
Dwight Babcock, CEO
![Page 2: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/2.jpg)
Fred Swindler Bill Cavanagh
Brien Ragle Krista Cline
Dale Boyce Clay O’Laughlin
![Page 3: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/3.jpg)
Brachytherapy
External Beam
Robotic Surgery
Proton Beam
Task Force Report
![Page 4: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/4.jpg)
Gliobastoma Brain Cancer Metastatic Brain Cancer Meningioma Brain Tumors Head and Neck Cancer Non Small Cell Lung Cancer Gynecologic Cancer
![Page 5: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/5.jpg)
Prostate – Consolidation of I-125 & P-103 Brain Cancers and Tumors – None GliaSite Balloon Radiation Therapy – None Lung Cancer – I-125 sutured seeds No Mesh Gynecologic Cancer - None
*Published Papers Are Needed Prior To General Adoption
![Page 6: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/6.jpg)
Pharma Model
Product development and pre-human testing: 5 years
Human Clinical Trials: 5 years
FDA Approval: 2 years
Adoption
IsoRay Prostate ModelProduct development 510(k) FDA Approval 1-2 years
Early Adopters DataPublished Papers
5-6 years
Wider Scale Adoption
IsoRay New Product ModelProduct development 510(k) FDA Approval
1-2 years
Early Adopters DataPublished Papers
1-3 years
Wider Scale Adoption
![Page 7: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/7.jpg)
Cornell Weill – Lung Cancer Cornell Weill – Metastatic Brain Cancer Archibold Medical – Lung Cancer MD Anderson – Intermediate Prostate
Cancer Sylvestor – Dual Therapy Prostate Cancer Cole – Mono Therapy Prostate Cancer Barrows – Meningioma Brain Tumors
![Page 8: 2013 Annual Shareholder Meeting Dwight Babcock, CEO](https://reader035.vdocument.in/reader035/viewer/2022081604/56815fe5550346895dceea1f/html5/thumbnails/8.jpg)